Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LOS ANGELES, April 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zenas BioPharma, Inc., (“Zenas" or the "Company") (NASDAQ: ZBIO) investors that the firm has initiated an investigation...
-
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or...
-
Zenas BioPharma investors are encouraged to call Cohen Milstein's Molly Bowen, Esq. about becoming a lead plaintiff in the ZBIO stock drop class action.
-
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If...
-
Zenas BioPharma investors have until June 16 to sign up to become a Lead Plaintiff in this securities class action. For more information, call Molly Bowen.
-
Cohen Milstein continues lead plaintiff Search for Zenas BioPharma (ZBIO) securities fraud class action. Contact Molly Bowen, Esq. at 1 (202) 408-4600.
-
Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit
Cohen Milstein reminds Zenas BioPharma (ZBIO) investors of an opportunity to lead a securities fraud class action. Lead plaintiff deadline - June 16, 2025.
-
Cohen Milstein seeks Zenas BioPharma (ZBIO) investors to join and/or lead class action to hold Zenas BioPharma accountable for IPO-related fraud.
-
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you...
-
Cohen Milstein Encourages Zenas BioPharma Investors Who Lost Money Following IPO Stock Collapse to Call Firm to Potentially Join or Lead Class Action.